HIV-1-induced amyloid beta accumulation in brain endothelial cells is attenuated by simvastatin

Molecular and Cellular Neuroscience

Volumn 43, Issue 2, 2010, Pages 232-243

  András, Ibolya E ^a   Eum, Sung Yong ^a   Huang, Wen ^a   Zhong, Yu ^a   Hennig, Bernhard ^b   Toborek, Michal ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Amyloid beta; Blood brain barrier; HIV 1; Human brain microvascular endothelial cells; Statins

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; LIPOPROTEIN; LIPOPROTEIN RELATED PROTEIN 1; SIMVASTATIN; UNCLASSIFIED DRUG;

ARTICLE; BIOACCUMULATION; BLOOD BRAIN BARRIER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT;

AMYLOID BETA-PROTEIN; BRAIN; CELL LINE, TRANSFORMED; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HIV-1; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LDL-RECEPTOR RELATED PROTEIN 1; PEPTIDE FRAGMENTS; RECEPTORS, IMMUNOLOGIC; SIMVASTATIN; TIME FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 73249132000     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcn.2009.11.004     Document Type: Article

References (41)

1. Achim C.L., Adame A., Dumaop W., Everall I.P., and Masliah E. Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J. Neuroimmune Pharmacol. 4 (2009) 190-199
2. Andras I.E., Rha G., Huang W., Eum S., Couraud P.O., Romero I.A., Hennig B., and Toborek M. Simvastatin protects against amyloid beta and HIV-1 Tat-induced promoter activities of inflammatory genes in brain endothelial cells. Mol. Pharmacol. 73 (2008) 1424-1433
3. Bhaskaran K., Mussini C., Antinori A., Walker A.S., Dorrucci M., Sabin C., Phillips A., and Porter K. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann. Neurol. 63 (2008) 213-221
4. Blanc E.M., Toborek M., Mark R.J., Hennig B., and Mattson M.P. Amyloid beta-peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells. J. Neurochem. 68 (1997) 1870-1881
5. Brew B.J., Crowe S.M., Landay A., Cysique L.A., and Guillemin G. Neurodegeneration and ageing in the HAART era. J. Neuroimmune Pharmacol. 4 (2009) 163-174
6. Chen X., Walker D.G., Schmidt A.M., Arancio O., Lue L.F., and Yan S.D. RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr. Mol. Med. 7 (2007) 735-742
7. Clifford P.M., Zarrabi S., Siu G., Kinsler K.J., Kosciuk M.C., Venkataraman V., D'Andrea M.R., Dinsmore S., and Nagele R.G. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res. 1142 (2007) 223-236
8. Deane R., and Zlokovic B.V. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 4 (2007) 191-197
9. Deane R., Du Yan S., Submamaryan R.K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J., Zhu H., Ghiso J., Frangione B., Stern A., Schmidt A.M., Armstrong D.L., Arnold B., Liliensiek B., Nawroth P., Hofman F., Kindy M., Stern D., and Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9 (2003) 907-913
10. Deane R., Wu Z., and Zlokovic B.V. RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35 (2004) 2628-2631
11. Donahue J.E., Flaherty S.L., Johanson C.E., Duncan III J.A., Silverberg G.D., Miller M.C., Tavares R., Yang W., Wu Q., Sabo E., Hovanesian V., and Stopa E.G. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol. 112 (2006) 405-415
12. Esiri M.M., Biddolph S.C., and Morris C.S. Prevalence of Alzheimer plaques in AIDS. J. Neurol. Neurosurg. Psychiatry 65 (1998) 29-33
13. Gilbert C., Bergeron M., Methot S., Giguere J.F., and Tremblay M.J. Statins could be used to control replication of some viruses, including HIV-1. Viral Immunol. 18 (2005) 474-489
14. Giometto B., An S.F., Groves M., Scaravilli T., Geddes J.F., Miller R., Tavolato B., Beckett A.A., and Scaravilli F. Accumulation of beta-amyloid precursor protein in HIV encephalitis: relationship with neuropsychological abnormalities. Ann. Neurol. 42 (1997) 34-40
15. Green D.A., Masliah E., Vinters H.V., Beizai P., Moore D.J., and Achim C.L. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 19 (2005) 407-411
16. Greenwood J., and Mason J.C. Statins and the vascular endothelial inflammatory response. Trends Immunol. 28 (2007) 88-98
17. Guan H., Liu Y., Daily A., Police S., Kim M.H., Oddo S., LaFerla F.M., Pauly J.R., Murphy M.P., and Hersh L.B. Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease. J. Neurosci. Res. 87 (2009) 1462-1473
18. Hamel F.G., Fawcett J., Tsui B.T., Bennett R.G., and Duckworth W.C. Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells. Diabetes Obes. Metab. 8 (2006) 661-668
19. Herring A., Yasin H., Ambree O., Sachser N., Paulus W., and Keyvani K. Environmental enrichment counteracts Alzheimer's neurovascular dysfunction in TgCRND8 mice. Brain Pathol. 18 (2008) 32-39
20. Miller M.C., Tavares R., Johanson C.E., Hovanesian V., Donahue J.E., Gonzalez L., Silverberg G.D., and Stopa E.G. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res. 1230 (2008) 273-280
21. Miners J.S., Baig S., Palmer J., Palmer L.E., Kehoe P.G., and Love S. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol. 18 (2008) 240-252
22. Paris D., Townsend K.P., Obregon D.F., Humphrey J., and Mullan M. Pro-inflammatory effect of freshly solubilized beta-amyloid peptides in the brain. Prostaglandins Other Lipid Mediat. 70 (2002) 1-12
23. Pascale J.M., Isaacs M.D., Contreras P., Gomez B., Lozano L., Austin E., De Martin M.C., Gregory R.L., McLaughlin G.L., and Amador A. Immunological markers of disease progression in patients infected with the human immunodeficiency virus. Clin. Diagn. Lab. Immunol. 4 (1997) 474-477
24. Pulliam L. HIV regulation of amyloid beta production. J. Neuroimmune Pharmacol. 4 (2009) 213-217
25. Rangachari V., Moore B.D., Reed D.K., Sonoda L.K., Bridges A.W., Conboy E., Hartigan D., and Rosenberry T.L. Amyloid-beta(1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate. Biochemistry 46 (2007) 12451-12462
26. Rempel H.C., and Pulliam L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS 19 (2005) 127-135
27. Rogers J., Mastroeni D., Leonard B., Joyce J., and Grover A. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?. Int. Rev. Neurobiol. 82 (2007) 235-246
28. Sagare A., Deane R., Bell R.D., Johnson B., Hamm K., Pendu R., Marky A., Lenting P.J., Wu Z., Zarcone T., Goate A., Mayo K., Perlmutter D., Coma M., Zhong Z., and Zlokovic B.V. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat. Med. 13 (2007) 1029-1031
29. Schmidt A.M., Hori O., Cao R., Yan S.D., Brett J., Wautier J.L., Ogawa S., Kuwabara K., Matsumoto M., and Stern D. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 45 Suppl. 3 (1996) S77-80
30. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehurst C., et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359 (1992) 325-327
31. Sondergaard T.E., Pedersen P.T., Andersen T.L., Soe K., Lund T., Ostergaard B., Garnero P., Delaisse J.M., and Plesner T. A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. Hematol. Oncol. 27 (2009) 17-22
32. Toborek M., Lee Y.W., Flora G., Pu H., Andras I.E., Wylegala E., Hennig B., and Nath A. Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell. Mol. Neurobiol. 25 (2005) 181-199
33. Tran H., Robinson S., Mikhailenko I., and Strickland D.K. Modulation of the LDL receptor and LRP levels by HIV protease inhibitors. J. Lipid Res. 44 (2003) 1859-1869
34. Valcour V., Shikuma C., Shiramizu B., Watters M., Poff P., Selnes O., Holck P., Grove J., and Sacktor N. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging With HIV-1 Cohort. Neurology 63 (2004) 822-827
35. Weksler B.B., Subileau E.A., Perriere N., Charneau P., Holloway K., Leveque M., Tricoire-Leignel H., Nicotra A., Bourdoulous S., Turowski P., Male D.K., Roux F., Greenwood J., Romero I.A., and Couraud P.O. Blood-Brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 19 (2005) 1872-1874
36. Xu J., and Ikezu T. The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J. Neuroimmune Pharmacol 4 (2009) 200-212
37. Yamada K., Hashimoto T., Yabuki C., Nagae Y., Tachikawa M., Strickland D.K., Liu Q., Bu G., Basak J.M., Holtzman D.M., Ohtsuki S., Terasaki T., and Iwatsubo T. The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid beta peptides in an in vitro model of the blood-brain barrier cells. J. Biol. Chem. 283 (2008) 34554-34562
38. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., and Schmidt A.M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382 (1996) 685-691
39. Yan S.D., Zhu H., Zhu A., Golabek A., Du H., Roher A., Yu J., Soto C., Schmidt A.M., Stern D., and Kindy M. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat. Med. 6 (2000) 643-651
40. Zlokovic B.V. New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics 5 (2008) 409-414
41. Zlokovic B.V., Yamada S., Holtzman D., Ghiso J., and Frangione B. Clearance of amyloid beta-peptide from brain: transport or metabolism?. Nat. Med. 6 (2000) 718-719